journal
https://read.qxmd.com/read/38483309/first-line-anlotinib-treatment-for-soft-tissue-sarcoma-in-chemotherapy-ineligible-patients-an-open-label-single-arm-phase-2-clinical-trial
#21
JOURNAL ARTICLE
Tao Li, Ying Dong, Yongzhong Wei, Shoufeng Wang, Yunxia Liu, Jia Chen, Wenhua Xiong, Nong Lin, Xin Huang, Meng Liu, Xiaobo Yan, Zhaoming Ye, Binghao Li
PURPOSE: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma (LPS). PATIENTS AND METHODS: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases...
March 14, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38477824/translational-frontiers-and-clinical-opportunities-of-immunologically-fitted-radiotherapy
#22
JOURNAL ARTICLE
Daphné Morel, Charlotte Robert, Nikos Paragios, Vincent Grégoire, Eric Deutsch
Ionising radiations can have a wide range of impacts on tumour-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity towards a suboptimal state. This may impair the full recovery of a sustained and efficient anti-tumour immunosurveillance post-treatment. An emerging concept is arising from this awareness and consists in re-considering the way of designing radiation treatment plannings, notably by taking into account the individualised risks of deleterious radio-induced immune alteration that can be deciphered from the planned beam trajectory through lymphocyte-rich organs...
March 13, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38470545/cell-free-dna-concentration-as-a-biomarker-of-response-and-recurrence-in-her2-negative-breast-cancer-receiving-neoadjuvant-chemotherapy
#23
JOURNAL ARTICLE
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, Lamorna Brown Swigart, Gillian L Hirst, Christina Yau, Denise M Wolf, Wen Li, Amy L Delson, Jane Perlmutter, Paula Pohlmann, W Fraser Symmans, Douglas Yee, Nola M Hylton, Laura J Esserman, Angela M DeMichele, Hope S Rugo, Laura J van 't Veer
PURPOSE: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value with cell-free DNA (cfDNA) concentration measured in the same samples from the same patients. EXPERIMENTAL DESIGN: 145 hormone receptor (HR)-positive/HER2-negative and 138 triple-negative breast cancer (TNBC) patients with ctDNA data from a previous study were included in the analysis...
March 12, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38470499/polo-like-kinase-1-inhibition-in-kras-mutated-metastatic-colorectal-cancer
#24
JOURNAL ARTICLE
Justin Stebbing, Andrea J Bullock
Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase 1 clinical trials.
March 12, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38470497/infiltrative-vessel-co-optive-growth-pattern-induced-by-iqgap3-overexpression-promotes-microvascular-invasion-in-hepatocellular-carcinoma
#25
JOURNAL ARTICLE
Miaoling Tang, Shuxia Zhang, Meisongzhu Yang, Rongni Feng, Jinbin Lin, Xiaohong Chen, Yingru Xu, Ruyuan Yu, Xinyi Liao, Ziwen Li, Xincheng Li, Man Li, Qiliang Zhang, Suwen Chen, Wanying Qian, Yuanji Liu, Libing Song, Jun Li
PURPOSE: Microvascular invasion (MVI) is a major unfavorable prognostic factor for intrahepatic metastasis and postoperative recurrence of hepatocellular carcinoma (HCC). However, the intervention and preoperative prediction for MVI remain clinical challenges due to the absent precise mechanism and molecular marker(s). Herein, we aimed to investigate the mechanisms underlying vascular invasion that can be applied to clinical intervention for MVI in HCC. EXPERIMENTAL DESIGN: The histopathological characteristics of clinical MVI+/HCC specimens were analyzed using multiplex immunofluorescence staining...
March 12, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38466644/biomarkers-of-efficacy-and-safety-of-the-academic-bcma-cart-ari0002h-for-the-treatment-of-refractory-multiple-myeloma
#26
JOURNAL ARTICLE
Aina Oliver-Caldés, Marta Español-Rego, Aintzane Zabaleta, Veronica Gonzalez-Calle, Sergio Navarro-Velázquez, Susana Inoges, Ascensión López-Díaz de Cerio, Valentin Cabañas, Nieves López-Muñoz, Paula Rodriguez-Otero, Juan Luis Reguera-Ortega, David F Moreno, Núria Martínez-Cibrian, Lucía López-Corral, Lorena Pérez-Amill, Beatriz Martin-Antonio, Laura Rosinol, Joan Cid, Natalia Tovar, Joaquin Saez-Peñataro, Miriam Lopez-Parra, Eulalia Olesti, Elena Guillen, Sara Varea, Luis Gerardo Rodríguez-Lobato, Anthony M Battram, Marta-Sonia Gonzalez-Perez, Andres Sanchez-Salinas, Azucena González-Navarro, Valentin Ortiz-Maldonado, Julio Delgado, Felipe Prosper, Manel Juan, Joaquin Martinez-Lopez, Jose M Moraleda, Maria Victoria Mateos, Alvaro Urbano-Ispizua, Bruno Paiva, Mariona Pascal, Carlos Fernández de Larrea
BACKGROUND: BCMA-CARTs improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated with CART therapy might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers and resistance mechanisms need to be identified and addressed to improve efficacy and patient selection. Here, we present clinical and ancillary results of the 60 patients treated with the academic BCMA-CART, ARI0002h, in the CARTBCMA-HCB-01 trial...
March 11, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38466643/tumor-infiltrating-lymphocytes-refine-outcomes-in-triple-negative-breast-cancer-treated-with-anthracycline-free-neoadjuvant-chemotherapy
#27
JOURNAL ARTICLE
Miguel Martín, Rachel Yoder, Roberto Salgado, Maria Del Monte-Millán, Enrique L Alvarez, Isabel Echavarría, Joshua M Staley, Anne P O'Dea, Lauren E Nye, Shane R Stecklein, Coralia Bueno Muiño, Yolanda Jerez-Gilarranz, María Cebollero, Oscar Bueno, Jose Ángel Garcia-Saenz, Fernando Moreno, Uriel Bohn, Henry Gomez, Tatiana Massarrah, Qamar J Khan, Andrew K Godwin, Sara López-Tarruella, Priyanka Sharma
BACKGROUND: Stromal tumor-infiltrating lymphocytes (sTILs) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in setting of anthracycline-based chemotherapy. Impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known. PATIENTS & METHODS: This is pooled analysis of two studies where patients with stage I(T>1cm)-III TNBC received carboplatin(AUC 6) plus docetaxel(75mg/m2) (CbD) NAC...
March 11, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38457288/a-phase-ii-open-label-randomized-clinical-trial-of-preoperative-durvalumab-or-durvalumab-plus-tremelimumab-in-resectable-head-and-neck-squamous-cell-carcinoma
#28
JOURNAL ARTICLE
Chang Gon Kim, Min Hee Hong, Dahee Kim, Brian Hyohyoung Lee, Hyunwook Kim, Chan-Young Ock, Geoffrey Kelly, Yoon Ji Bang, Gamin Kim, Jung Eun Lee, Chaeyeon Kim, Se-Heon Kim, Hyun Jun Hong, Young Min Park, Nam Suk Sim, Heejung Park, Jin Woo Park, Chang Geol Lee, Kyung Hwan Kim, Goeun Park, Inkyung Jung, Dawoon Han, Jong Hoon Kim, Junha Cha, Insuk Lee, Mingu Kang, Heon Song, Chiyoon Oum, Seulki Kim, Sukjun Kim, Yoojoo Lim, Seunghee Kim-Schulze, Miriam Merad, Sun Och Yoon, Hyun Je Kim, Yoon Woo Koh, Hye Ryun Kim
PURPOSE: Clinical implications of neoadjuvant immunotherapy in patients with locally advanced but resectable head and neck squamous cell carcinoma (HNSCC) remain largely unexplored. PATIENTS AND METHODS: Patients with resectable HNSCC were randomized to receive a single dose of preoperative durvalumab (D) with or without tremelimumab (T) before resection, followed by postoperative (chemo)radiation based on multidisciplinary discretion and 1-year D treatment. Artificial intelligence (AI)-powered spatial distribution analysis of tumor-infiltrating lymphocytes and high-dimensional profiling of circulating immune cells tracked dynamic intratumoral and systemic immune responses...
March 8, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38456660/phase-1-2-study-of-combined-bcl-xl-and-mek-inhibition-with-navitoclax-and-trametinib-in-kras-or-nras-mutant-advanced-solid-tumors
#29
JOURNAL ARTICLE
Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
PURPOSE: MEK inhibitors (MEKi) lack monotherapy efficacy in most RAS-mutant cancers. BCL-xL is an anti-apoptotic protein identified by a synthetic lethal shRNA screen as a key suppressor of apoptotic response to MEKi. PATIENTS AND METHODS: We conducted a dose escalation study (NCT02079740) of the BCL-xL inhibitor navitoclax and MEKi trametinib in patients with RAS-mutant tumors with expansion cohorts for: pancreatic, gynecologic (GYN), non-small cell lung cancer (NSCLC), and other cancers harboring KRAS/NRAS mutations...
March 8, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38451486/targeting-ccl2-ccr2-signaling-overcomes-mek-inhibitor-resistance-in-acute-myeloid-leukemia
#30
JOURNAL ARTICLE
Rucha V Modak, Katia G de Oliveira Rebola, John McClatchy, Mona Mohammadhosseini, Alisa Damnernsawad, Stephen E Kurtz, Christopher A Eide, Guanming Wu, Ted Laderas, Tamilla Nechiporuk, Marina A Gritsenko, Joshua R Hansen, Chelsea Hutchinson, Sara J C Gosline, Paul Piehowski, Daniel Bottomly, Nicholas Short, Karin Rodland, Shannon K McWeeney, Jeffrey W Tyner, Anupriya Agarwal
PURPOSE: Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions, driving disease progression, and promoting drug resistance in acute myeloid leukemia (AML). This emphasizes the need for the identification of targeted therapies that inhibit intrinsic and extrinsic signaling to overcome drug resistance in AML. EXPERIMENTAL DESIGN: We performed a comprehensive analysis utilizing a cohort of ~300 AML patient samples...
March 7, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38451195/therapeutic-targeting-of-tim-4-l-with-engineered-t-cells-for-acute-myeloid-leukemia
#31
JOURNAL ARTICLE
Brandon Cieniewicz, Edson Oliveira, Mike Saxton, Damoun Torabi, Ankit Bhatta, Phanidhar Kukutla, Alexander Arballo, Zhuo Yang, Bi Yu, Maria Fate, Hongxiu Ning, Lawrence Corey, Abhishek Maiti, Daniel Corey
PURPOSE: Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We utilized the natural immune receptor TIM-4 to interrogate for loss of plasma membrane phospholipid polarity in primary acute myelogenous leukemia (AML) samples and evaluated the anti-leukemic activity of TIM-4-L-directed T cell therapy in preclinical AML models. METHODS: We performed FACs analysis on 33 primary AML bone marrow specimens and correlated TIM-4-L expression frequency and intensity with molecular disease characteristics...
March 7, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38446993/plasma-proteomic-signature-predicts-myeloid-neoplasm-risk
#32
JOURNAL ARTICLE
Duc Tran, J Scott Beeler, Jie Liu, Brian Wiley, Irenaeus C C Chan, Zilan Xin, Michael H Kramer, Armel L Batchi-Bouyou, Xiaoyu Zong, Matthew J Walter, Giulia E M Petrone, Sarantis Chlamydas, Francesca Ferraro, Stephen T Oh, Daniel C Link, Ben Busby, Yin Cao, Kelly L Bolton
PURPOSE: Clonal hematopoiesis (CH) is thought to be the origin of myeloid neoplasms (MN). Yet our understanding of the mechanisms driving CH progression to MN and clinical risk prediction of MN remains limited. The human proteome reflects complex interactions between genetic and epigenetic regulation of biological systems. We hypothesized that the plasma proteome might predict MN risk and inform our understanding of the mechanisms promoting MN development. EXPERIMENTAL DESIGN: We jointly characterized CH and plasma proteomic profiles of 46,237 individuals in the UK Biobank at baseline study entry...
March 6, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38446990/a-single-arm-phase-2-trial-of-trametinib-in-patients-with-locally-advanced-or-metastatic-epithelioid-hemangioendothelioma
#33
JOURNAL ARTICLE
Scott M Schuetze, Karla V Ballman, Rachel Heise, Kristen N Ganjoo, Elizabeth J Davis, Suzanne George, Melissa A Burgess, Edwin Choy, Dale R Shepard, Gabriel Tinoco, Angela Hirbe, Ciara M Kelly, Steven Attia, Hari A Deshpande, Gary K Schwartz, Brittany L Siontis, Richard F Riedel, Margaret von Mehren, Erin Kozlowski, Helen X Chen, Caroline Astbury, Brian P Rubin
PURPOSE: Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ-CAMTA1 operating as an oncogenic driver through activation of MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE. PATIENTS AND METHODS: A phase 2 trial of trametinib was conducted in patients with locally advanced or metastatic EHE. Eligibility requirements included evidence of tumor progression or presence of EHE-related pain requiring opiates for management prior to enrollment...
March 6, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38446982/response-rate-and-molecular-correlates-to-encorafenib-and-binimetinib-in-braf-v600e-mutant-high-grade-glioma
#34
JOURNAL ARTICLE
Karisa C Schreck, Roy E Strowd, Louis B Nabors, Benjamin M Ellingson, Michael Chang, Sze K Tan, Zied Abdullaev, Rust Turakulov, Kenneth Aldape, Neeraja Danda, Serena Desideri, Joy Fisher, Michaella Iacoboni, Trisha Surakus, Michelle A Rudek, Chetan Bettegowda, Stuart A Grossman, Xiaobu Ye
PURPOSE: While fewer than 5% of high-grade gliomas (HGG) are BRAF-V600E mutated, these tumors are notable as BRAF-targeted therapy shows efficacy for some populations. The purpose of this study was to evaluate response to the combination of encorafenib with binimetinib in adults with recurrent BRAF-V600 mutated HGG. PATIENTS AND METHODS: In this phase 2, open-label, Adult Brain Tumor Consortium (ABTC) trial (NCT03973918), encorafenib and binimetinib were administered at their FDA-approved doses continuously in 28-day cycles...
March 6, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38441659/mesenchymal-stem-stromal-cell-therapy-for-radiation-induced-xerostomia-in-previous-head-and-neck-cancer-patients-a-phase-2-randomised-placebo-controlled-trial
#35
JOURNAL ARTICLE
Kathrine Jakobsen, Amanda-Louise Fenger Carlander, Tobias Todsen, Jacob Melchiors, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Christine Mordhorst, Helene Stampe, Jens Kastrup, Annette Ekblond, Mandana Haack-Sørensen, Mohammad Farhadi, Christian Maare, Jeppe Friborg, Charlotte Duch Lynggaard, Anne Werner Hauge, Robin Christensen, Christian Grønhøj, Christian von Buchwald
PURPOSE: No effective treatment exists for radiation-induced xerostomia. The objective of this study was to compare the effect of adipose-derived mesenchymal stem/stromal cell (ASC) injection, relative to placebo, on salivary gland function in patients with radiation-induced xerostomia. PATIENT AND METHODS: In this single-centre, double-blind, placebo-controlled trial, patients with hyposalivation were randomised to receive ultrasound-guided injections of allogeneic ASCs or placebo into the submandibular glands...
March 5, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38441576/fda-approval-summary-enfortumab-vedotin-plus-pembrolizumab-for-cisplatin-ineligible-locally-advanced-or-metastatic-urothelial-carcinoma
#36
JOURNAL ARTICLE
William F Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S Hamed, Erik W Bloomquist, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
On April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Substantial evidence of effectiveness was obtained from EV-103/KEYNOTE-869 (NCT03288545), a multi-cohort study. Across cohorts, a total of 121 patients received EV 1.25 mg/kg (maximum of 125 mg) intravenously on days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle until disease progression or unacceptable toxicity...
March 5, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38437679/a-pre-leukemic-dna-methylation-signature-in-healthy-individuals-at-higher-risk-for-developing-myeloid-malignancy
#37
JOURNAL ARTICLE
Zhentang Lao, Ling-Wen Ding, Qiao-Yang Sun, Li Jia, Benedict Yan, Alvin Yu-Jin Ng, Sharah Mae Capinpin, Renwei Wang, Li Ying, Wee Joo Chng, H Phillip Koeffler, Woon-Puay Koh, Jian-Min Yuan, Henry Yang, Yeow Tee Goh, Nicholas Grigoropoulos
PURPOSE: DNA methylation alterations are widespread in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), some of which appear to have evolved independently of somatic mutations in epigenetic regulators. While the presence of somatic mutations in peripheral blood can predict the risk of development of AML and MDS, its accuracy remains unsatisfactory. EXPERIMENTAL DESIGN: We performed global DNA methylation profiling in a case-control study nested within Singapore Chinese Health Study to evaluate if DNA methylation alterations were associated with AML/MDS development...
March 4, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38437671/the-irreversible-fgfr-inhibitor-kin-3248-overcomes-fgfr2-kinase-domain-mutations
#38
JOURNAL ARTICLE
Eranga R Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S Silveira, Nabeel Bardeesy
PURPOSE: FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC) and bladder cancers, respectively, and multiple selective reversible and covalent pan-FGFR tyrosine kinase inhibitors (TKIs) have been approved in these contexts. However, resistance, often due to acquired secondary mutations in the FGFR2/3 kinase domain, limits efficacy...
March 4, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38433347/trastuzumab-and-pertuzumab-in-patients-with-non-breast-gastroesophageal-her2-amplified-tumors-results-from-the-nci-match-ecog-acrin-trial-eay131-subprotocol-j
#39
JOURNAL ARTICLE
Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Jue Wang, Kari B Wisinski, James V Tricoli, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty
PURPOSE: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across HER2-amplified tumors. PATIENTS AND METHODS: Eligible patients had high levels of HER2 amplification [copy number (CN) ≥7] detected by central next-generation sequencing (NGS) or through NCI-designated laboratories. Patients with breast/gastroesophageal adenocarcinoma and those who received prior HER2-directed therapy were excluded...
March 4, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38427437/radiotherapy-enhances-metastasis-through-immune-suppression-by-inducing-pd-l1-and-mdsc-in-distal-sites
#40
JOURNAL ARTICLE
Yuzhu Hou, Kaiting Yang, Liangliang Wang, Jiaai Wang, Xiaona Huang, Andras Piffko, Sean Z Luo, Xinshuang Yu, Enyu Rao, Carlos Martinez, Jason Bugno, Matthias Mack, Everett E Vokes, Sean P Pitroda, Steven J Chmura, Ralph R Weichselbaum, Hua Laura Liang
PURPOSE: Radiotherapy (RT) is a widely employed anti-cancer treatment. Emerging evidence suggests that RT can elicit both tumor-inhibiting and tumor-promoting immune effects. This study is to investigate immune suppressive factors of radiotherapy. EXPERIMENTAL DESIGN: We used a heterologous two-tumor model in which adaptive concomitant immunity was eliminated. RESULTS: Through analysis of PD-L1 expression and MDSC frequencies using patient PBMC and murine two-tumor and metastasis model, we report that local irradiation can induce a systemic increase in MDSCs, as well as PD-L1 expression on DCs and myeloid cells, and thereby increase the potential for metastatic dissemination in distal, non-irradiated tissue...
March 1, 2024: Clinical Cancer Research
journal
journal
20070
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.